Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Kura Oncology Inc.
Headquarters: San Diego, CA, United States of America
Website: http://www.kuraoncology.com
Year Founded: 2014
Status: Public
Industry Sector: HealthTechnology
CEO: Troy E. Wilson, PhD
Number Of Employees: 192
Enterprise Value: $39,661,310
PE Ratio: -3.05
Exchange/Ticker 1: NASDAQ:KURA
Exchange/Ticker 2: N/A
Latest Market Cap: $498,258,400
BioCentury | Jan 11, 2025
Management Tracks
Faces in new places ahead of JPM: Rubin joining Guggenheim
Week’s management moves include new venture partners at Frazier and updates from Beigene, Intellia and more
BioCentury | Jan 8, 2025
Management Tracks
New CMOs for Alltrna, Kura, Aro
Plus: Monahan becomes chief commercial officer of Amylyx and more
BioCentury | Nov 26, 2024
Deals
Kyowa Kirin brings global reach to Kura’s menin program via licensing deal
Also in BioCentury’s Deals Report: Novartis buys gene therapy play Kate, Telix buys FAP-targeting theranostics, and more
BioCentury | Nov 13, 2024
Product Development
Adverse event casts shadow over Neurogene’s Rett syndrome readout
BioCentury’s Clinical Report also analyzes data from Syndax and Gan & Lee, plus pipeline updates from Sarepta, Tango and RAPT
BioCentury | Jan 31, 2024
Product Development
Clinical roundup: Data for Vertex, Sarepta, Lilly, Alligator, Corbus and Vera
Vertex’s analgesic heads for submission; plus the latest from Sarepta in DMD, Lilly in hearing loss, and more
BioCentury | Jan 27, 2024
Finance
Public equity roundup: CG, ArriVent IPOs stoke optimism for growing queue
Plus: Follow-ons for Sagimet, Tourmaline and Adicet, and PIPEs for Kura, ORIC and CalciMedica
BioCentury | Aug 14, 2023
Management Tracks
Gardner named CEO of Flagship’s Ampersand
Plus: Brian Powl joins Kura as CCO, and updates from BioNTech, Allogene, CG and more
BioCentury | Feb 1, 2023
Product Development
Navigating dose optimization requirements as a small biotech
FDA’s dose optimization push presents a burden for some small biotechs, and an opportunity for others
BioCentury | Nov 4, 2022
Regulation
Nov. 3 Quick Takes: FDA delay could shorten Apellis’ lead in geographic atrophy
Plus NextCure abandons SIGLEC15 and updates from Emalex, Moderna, Aurinia, Affimed, Artiva and more
Items per page:
1 - 10 of 70